---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-081445"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:12:48.675484+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics reports FY 2022 net loss $31.2M, cash runway into Q4 2024

## Summary
- Net loss for FY 2022 was $31.2M vs $16.2M in 2021; Q4 net loss $8.9M vs $4.3M.
- R&D expenses $23.9M in 2022, driven by ACR-368 Phase 2 trial and companion diagnostic agreement.
- Cash, cash equivalents and marketable securities $169.6M as of Dec 31, 2022; expected to fund operations at least into Q4 2024.
- FDA clearance received for IND of ACR-368 Phase 2 trial in platinum-resistant ovarian, endometrial, and urothelial cancers.
- Initial Phase 2 data expected in second half of 2023; WEE1 and PKMYT1 programs advancing toward IND-enabling studies.

## SEC filing metadata
- accession: 0001193125-23-081445
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/d464039d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-081445
- JSON: https://secwatch.observer/filing/0001193125-23-081445.json
- Plain text: https://secwatch.observer/filing/0001193125-23-081445.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income $31.2 million.
  - Period: the full year ended December 31, 2022
  - Net income: $31.2 million
  - Result: reported results
  source text: Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm
- Earnings Releases
  Acrivon Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.9 million.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: $8.9 million
  - Result: reported results
  source text: Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.